No abstract

No abstract

Students' recruitment and retention was scarce, mainly in Spain. However students involved visited the program website with sufficient amount of time to achieve good results.

No abstract

S7of pembrolizumab in kr is 1M, 1.3M, 999K, 795K, and 816K, respectively. Among all the indicated population, the weighted cost per QALY was kr 1M/QALY. The results of sensitivity analyses for other key model parameters were robust. ConCluSionS: A holistic cost-effectiveness model of multi-indication drugs provides HTA bodies a useful tool to evaluate the overarching value of anti-cancer drugs and to alleviate the burden of repetitive appraisals in the era of targeted therapies. Analyses show the cost-effectiveness of pembrolizumab vary across indications due to the differential clinical profiles and demonstrate overall cost-effectiveness across indicated indications in Norway. HT3Using Real-WoRld evidence foR HealTH TecHnology assessmenT sUbmissions: lessons and insigHTs fRom RevieW of nice's TecHnology assessmenT RepoRTs (2016)(2017)